Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Protagonist Therapeutics, Inc. - Common Stock (NQ:PTGX)

76.49 -0.45 (-0.58%)
Streaming Delayed Price Updated: 11:08 AM EDT, Oct 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 230,752
Open 75.29
Bid (Size) 76.27 (1)
Ask (Size) 76.60 (4)
Prev. Close 76.94
Today's Range 75.29 - 76.52
52wk Range 33.31 - 93.25
Shares Outstanding 62,107,572
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Johnson & Johnson To Separate Orthopedics Business, Boosts Annual Sales Outlook
Johnson & Johnson beats Q3 estimates, raises 2025 sales guidance, and announces plans to spin off its $9.2 billion orthopedics business, DePuy Synthes. 
Via Benzinga
Johnson & Johnson Stock Falls Premarket: Investors Eye MedTech Growth, Tariff Impact And Drug Pipeline In Q3 Print
Investors may also look for updates on J&J’s reported talks to acquire Protagonist Therapeutics to bolster its immunology and oncology pipeline. 
Via Stocktwits
Topics Government World Trade

Performance

YTD
+96.2%
+96.2%
1 Month
+31.0%
+31.0%
3 Month
+38.3%
+38.3%
6 Month
+62.9%
+62.9%
1 Year
+65.0%
+65.0%

More News

Read More
BMO Capital Lifts Protagonist Therapeutics Target On J&J Deal Hopes — Retail Traders Pile In
Via Stocktwits
Johnson & Johnson Q3 Preview: With Stock Near All-Time Highs, Here's What To Watch
Via Benzinga
FDA Adds New Warning For Johnson & Johnson's Cancer Cell Therapy
Via Benzinga
Wall Street Suffers Worst Day Since April as Trump Revives Trade War Fears
Via Chartmill
Topics Artificial Intelligence Government World Trade
Why Protagonist Therapeutics Stock Skyrocketed by Almost 30% Today
Via The Motley Fool
Let's have a look at the top gainers and losers one hour before the close of the markets of today's session.
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Johnson & Johnson In Talks To Acquire Protagonist Therapeutics: Report
Via Benzinga
Which stocks are experiencing notable movement on Friday?
Via Chartmill
5 Analysts Assess Protagonist Therapeutics: What You Need To Know
Via Benzinga
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill
Via ACCESS Newswire
Demystifying Protagonist Therapeutics: Insights From 4 Analyst Reviews
Via Benzinga
Johnson & Johnson, Protagonist Study Shows Superior Skin Clearance In Psoriasis Trials
Via Benzinga
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Via Benzinga
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress
Via ACCESS Newswire
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025
Via ACCESS Newswire
This Protagonist Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Friday
Via Benzinga
Protagonist Announces Icotrokinra Application for Approval in Plaque Psoriasis Submitted to the European Medicines Agency
Via ACCESS Newswire
Protagonist Therapeutics to Participate in Multiple Investment Bank Conferences in September 2025
Via ACCESS Newswire
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
Via ACCESS Newswire
What 4 Analyst Ratings Have To Say About Protagonist Therapeutics
Via Benzinga
Protagonist (PTGX) Q2 Revenue Falls 26%
Via The Motley Fool
Protagonist Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Via ACCESS Newswire

Frequently Asked Questions

Is Protagonist Therapeutics, Inc. - Common Stock publicly traded?
Yes, Protagonist Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Protagonist Therapeutics, Inc. - Common Stock trade on?
Protagonist Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Protagonist Therapeutics, Inc. - Common Stock?
The ticker symbol for Protagonist Therapeutics, Inc. - Common Stock is PTGX on the Nasdaq Stock Market
What is the current price of Protagonist Therapeutics, Inc. - Common Stock?
The current price of Protagonist Therapeutics, Inc. - Common Stock is 76.49
When was Protagonist Therapeutics, Inc. - Common Stock last traded?
The last trade of Protagonist Therapeutics, Inc. - Common Stock was at 10/15/25 11:08 AM ET
What is the market capitalization of Protagonist Therapeutics, Inc. - Common Stock?
The market capitalization of Protagonist Therapeutics, Inc. - Common Stock is 4.75B
How many shares of Protagonist Therapeutics, Inc. - Common Stock are outstanding?
Protagonist Therapeutics, Inc. - Common Stock has 5B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.